Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.54 |
| ▸ | VDR | P11473 | 7/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106866 | 0.99 | HMGCR (0.55) | HMGCRVDRCYP24A1HDAC4MEF2D | |
| SCHEMBL2108299 | 0.91 | HMGCR (0.53) | HMGCRVDRCYP24A1HDAC4MEF2D | |
| SCHEMBL6155341 | 0.90 | HMGCR (0.54) | HMGCRVDRCYP24A1HDAC4MEF2D | |
| SCHEMBL2106285 | 0.83 | HMGCR (0.57) | HMGCR | |
| SCHEMBL2108148 | 0.83 | HMGCR (0.57) | HMGCR | |
| SCHEMBL2108149 | 0.83 | HMGCR (0.57) | HMGCR | |
| SCHEMBL2106283 | 0.83 | HMGCR (0.57) | HMGCR | |
| SCHEMBL2106842 | 0.82 | HMGCR (0.56) | HMGCRVDRCYP24A1 | |
| SCHEMBL6154933 | 0.82 | HMGCR (0.56) | HMGCRVDRCYP24A1HDAC4MEF2D | |
| SCHEMBL6154934 | 0.82 | HMGCR (0.56) | HMGCRVDRCYP24A1HDAC4MEF2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| US-20050169945-A1 | Composition for protecting keratin material, process of making, uses thereof | L'OREAL (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1559398-A1 | Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins | L'OREAL (FR) | 2005-08-03 | — | — | EP | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| EP-1262168-A1 | Composition containing fibres to combat the skin aging process | L'OREAL (FR) | 2002-12-04 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169945-A1 | Composition for protecting keratin material, process of making, uses thereof | KRT18, PROC, CUTA | HMGCR 1113/4885VDR 514/4885CYP24A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.